U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07883590) titled 'A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).' on Oct. 14.
Brief Summary: The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 13 weeks and will include 6 clinic visits.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis
Cytochrome P-450 Enzyme System
Int...